<html><head></head><body><h1>Opdivo</h1><p class="drug-subtitle"><b>Generic Name:</b> nivolumab (nye VOL ue mab)<br/>
<b>Brand Name:</b> <i>Opdivo</i></p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Warnings</li>
<li>Dosage</li>
<li>What to avoid</li>
<li>Side effects</li>
<li>Interactions</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="uses">What is Opdivo?</h2><p>Opdivo (nivolumab) is a cancer medicine that is used alone or in combination with other medicines that works with your immune system to interfere with the growth and spread of cancer cells in the body.</p><p>Opdivo is used alone or in combination with other medicines to treat adults with:</p><ul>
<li>
<p>advanced skin cancer (melanoma);</p>
</li>
<li>
<p>advanced non-small cell lung cancer;</p>
</li>
<li>
<p>pleural mesothelioma (cancer that affects the lining of the lungs and chest wall);</p>
</li>
<li>
<p>kidney cancer;</p>
</li>
<li>
<p>classical Hodgkin lymphoma;</p>
</li>
<li>
<p>squamous cell cancer of the esophagus or head and neck;</p>
</li>
<li>
<p>bladder cancer; or</p>
</li>
<li>
<p>liver cancer.</p>
</li>
</ul><p>advanced skin cancer (melanoma);</p><p>advanced non-small cell lung cancer;</p><p>pleural mesothelioma (cancer that affects the lining of the lungs and chest wall);</p><p>kidney cancer;</p><p>classical Hodgkin lymphoma;</p><p>squamous cell cancer of the esophagus or head and neck;</p><p>bladder cancer; or</p><p>liver cancer.</p><p>Opdivo is also used to treat adults and children 12 years and older with a type of colorectal cancer that laboratory testing proves to have certain specific DNA mutations.</p><p>Opdivo is often given when the cancer has spread to other parts of the body, or cannot be surgically removed, or has come back after prior treatment.</p><p>For advanced lung cancer, Opdivo is given only if your tumor is positive for a protein called PD-L1, and your tumor does not have a specific genetic marker (an abnormal "EGFR" or "ALK" gene).</p><h2 class="ddc-anchor-offset" id="warnings">Warnings</h2><p><b>Opdivo can cause side effects in many different parts of your body.</b> Some side effects may need to be treated with other medicine, and your cancer treatments may be delayed.</p><p>Call your doctor at once if you have: chest pain, cough, shortness of breath, vision changes, severe muscle pain or weakness, diarrhea and severe stomach pain, blood in your stools, little or no urinating, swelling, bruising or bleeding, dark urine, yellowing of the skin or eyes, confusion, skin blistering, sores in your mouth or nose or on your genitals, frequent headaches, dizziness, increased thirst or urination, numbness or tingling, feeling cold, or weight gain or loss.</p><h2>Before taking this medicine</h2><p>You should not use Opdivo if you are allergic to nivolumab.</p><p>To make sure Opdivo is safe for you, tell your doctor if you have ever had:</p><ul>
<li>
<p>lung disease or breathing problems;</p>
</li>
<li>
<p>liver disease;</p>
</li>
<li>
<p>an autoimmune disorder (lupus, Crohn's disease, ulcerative colitis); or</p>
</li>
<li>
<p>an organ transplant, or a stem cell transplant from a donor.</p>
</li>
</ul><p>lung disease or breathing problems;</p><p>liver disease;</p><p>an autoimmune disorder (lupus, Crohn's disease, ulcerative colitis); or</p><p>an organ transplant, or a stem cell transplant from a donor.</p><p><b>Do not use Opdivo if you are pregnant.</b> It could harm the unborn baby. Use effective birth control to prevent pregnancy while you are using this medicine and for at least 5 months after your last dose. Tell your doctor if you become pregnant.</p><p>You should not breast-feed while using this medicine.</p><h2>How is Opdivo given?</h2><p>Opdivo is given as an infusion into a vein by a healthcare provider. This medicine must be given slowly, and the infusion can take at least 30 minutes to complete.</p><p>Opdivo is usually given once every 2 to 4 weeks. Your other cancer medicines may be given on different schedules. Your doctor will determine how long to treat you with all medicines.</p><p>Your doctor will perform tests to make sure this medicine is the best treatment for your type of cancer.</p><p>You may be given medication to treat or prevent certain side effects of nivolumab.</p><p>Opdivo can cause side effects in many parts of your body by changing how your immune system works. Some side effects may be treated with other medicine, and your cancer treatments may be delayed or stopped.</p><p><b>You will need frequent medical tests to help your doctor determine if it is safe for you to keep receiving Opdivo.</b></p><h2 class="ddc-anchor-offset" id="dosage">Dosing information</h2><p><b>Usual Adult Dose for Melanoma -- Metastatic:</b></p><p>AS A SINGLE AGENT:<br/>
UNRESECTABLE OR METASTATIC MELANOMA:<br/>
240 mg IV over 30 minutes every 2 weeks until disease progression or unacceptable toxicity<br/>
OR<br/>
480 mg IV over 30 minutes every 4 weeks until disease progression or unacceptable toxicity<br/>
ADJUVANT TREATMENT OF MELANOMA:<br/>
240 mg IV over 30 minutes every 2 weeks until disease progression or unacceptable toxicity for up to one year<br/>
OR<br/>
480 mg IV over 30 minutes every 4 weeks until disease progression or unacceptable toxicity for up to one year<br/>
<br/>
IN COMBINATION:<br/>
UNRESECTABLE OR METASTATIC MELANOMA:<br/>
1 mg/kg IV over 30 minutes every 3 weeks with ipilimumab 3 mg/kg IV over 90 minutes on the same day for a maximum of 4 doses or until unacceptable toxicity, whichever occurs earlier<br/>
THEN:<br/>
240 mg IV over 30 minutes every 2 weeks; after completing 4 doses of combination therapy, administer as single agent until disease progression or unacceptable toxicity<br/>
OR<br/>
480 mg IV over 30 minutes every 4 weeks; after completing 4 doses of combination therapy, administer as single agent until disease progression or unacceptable toxicity<br/>
<br/>
Uses:<br/>
-As a single agent or in combination with ipilimumab, is indicated for the treatment of patients with unresectable or metastatic melanoma<br/>
-For the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection</p><p><b>Usual Adult Dose for Non-Small Cell Lung Cancer:</b></p><p>AS A SINGLE AGENT:<br/>
METASTATIC NON-SMALL CELL LUNG CANCER:<br/>
240 mg IV over 30 minutes every 2 weeks until disease progression or unacceptable toxicity<br/>
OR<br/>
480 mg IV over 30 minutes every 4 weeks until disease progression or unacceptable toxicity<br/>
SMALL CELL LUNG CANCER:<br/>
240 mg IV over 30 minutes every 2 weeks until disease progression or unacceptable toxicity<br/>
<br/>
IN COMBINATION:<br/>
METASTATIC OR RECURRENT NON-SMALL CELL LUNG CANCER EXPRESSING PD-L1:<br/>
3 mg/kg IV over 30 minutes every 2 weeks with ipilimumab 1 mg/kg IV over 30 minutes every 6 weeks until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression<br/>
METASTATIC OR RECURRENT NON-SMALL CELL LUNG CANCER:<br/>
360 mg IV over 30 minutes every 3 weeks with ipilimumab 1 mg/kg IV over 30 minutes every 6 weeks and histology-based platinum doublet chemotherapy every 3 weeks for the first 2 cycles, then 360 mg IV over 30 minutes every 3 weeks with ipilimumab 1 mg/kg IV over 30 minutes every 6 weeks until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression<br/>
<br/>
Uses:<br/>
-This drug, in combination with ipilimumab, is for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (1% or greater) with no EGFR or ALK genomic tumor aberrations<br/>
-This drug, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy, for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations<br/>
-For the treatment of patients with metastatic NSCLC with progression on or after platinum-based chemotherapy (patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving this drug</p><p><b>Usual Adult Dose for Renal Cell Carcinoma:</b></p><p>AS A SINGLE AGENT:<br/>
240 mg IV over 30 minutes every 2 weeks until disease progression or unacceptable toxicity<br/>
OR<br/>
480 mg IV over 30 minutes every 4 weeks until disease progression or unacceptable toxicity<br/>
<br/>
IN COMBINATION:<br/>
3 mg/kg IV over 30 minutes every 3 weeks with ipilimumab 1 mg/kg IV over 30 minutes on the same day for 4 doses<br/>
THEN AFTER COMPLETING 4 DOSES OF COMBINATION THERAPY, ADMINISTER AS SINGLE AGENT:<br/>
240 mg IV over 30 minutes every 2 weeks until disease progression or unacceptable toxicity<br/>
OR<br/>
480 mg IV over 30 minutes every 4 weeks until disease progression or unacceptable toxicity<br/>
<br/>
Uses:<br/>
-As a single agent for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy<br/>
-In combination with ipilimumab the treatment of patients with intermediate or poor risk, previously untreated advanced RCC</p><p><b>Usual Adult Dose for Hodgkin's Disease:</b></p><p>AS A SINGLE AGENT:<br/>
240 mg IV over 30 minutes every 2 weeks until disease progression or unacceptable toxicity<br/>
OR<br/>
480 mg IV over 30 minutes every 4 weeks until disease progression or unacceptable toxicity<br/>
<br/>
Use: For classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or 3 or more lines of systemic therapy that includes autologous HSCT</p><p><b>Usual Adult Dose for Head and Neck Cancer:</b></p><p>AS A SINGLE AGENT:<br/>
240 mg IV over 30 minutes every 2 weeks until disease progression or unacceptable toxicity<br/>
OR<br/>
480 mg IV over 30 minutes every 4 weeks until disease progression or unacceptable toxicity<br/>
<br/>
Use: For recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy</p><p><b>Usual Adult Dose for Urothelial Carcinoma:</b></p><p>AS A SINGLE AGENT:<br/>
240 mg IV over 30 minutes every 2 weeks until disease progression or unacceptable toxicity<br/>
OR<br/>
480 mg IV over 30 minutes every 4 weeks until disease progression or unacceptable toxicity<br/>
<br/>
Use: For locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy</p><p><b>Usual Adult Dose for Colorectal Cancer:</b></p><p>AS A SINGLE AGENT:<br/>
40 KG OR GREATER:<br/>
240 mg IV over 30 minutes every 2 weeks until disease progression or unacceptable toxicity<br/>
OR<br/>
480 mg IV over 30 minutes every 4 weeks until disease progression or unacceptable toxicity<br/>
<br/>
IN COMBINATION:<br/>
40 KG OR GREATER:<br/>
3 mg/kg IV over 30 minutes every 3 weeks with ipilimumab 1 mg/kg IV over 30 minutes on the same day for a total of 4 doses<br/>
AFTER COMPLETING 4 DOSES OF COMBINATION THERAPY, ADMINISTER AS SINGLE AGENT:<br/>
40 KG OR GREATER:<br/>
240 mg IV over 30 minutes every 2 weeks until disease progression or unacceptable toxicity<br/>
OR<br/>
480 mg IV over 30 minutes every 4 weeks until disease progression or unacceptable toxicity<br/>
<br/>
Use: As a single agent or in combination with ipilimumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan</p><p><b>Usual Adult Dose for Hepatocellular Carcinoma:</b></p><p>AS A SINGLE AGENT:<br/>
240 mg IV over 30 minutes every 2 weeks until disease progression or unacceptable toxicity<br/>
OR<br/>
480 mg IV over 30 minutes every 4 weeks until disease progression or unacceptable toxicity<br/>
<br/>
IN COMBINATION:<br/>
1 mg/kg IV over 30 minutes every 3 weeks with ipilimumab 3 mg/kg IV over 30 minutes on the same day for 4 doses<br/>
THEN AFTER COMPLETING 4 DOSES OF COMBINATION THERAPY, ADMINISTER AS SINGLE AGENT:<br/>
240 mg IV over 30 minutes every 2 weeks until disease progression or unacceptable toxicity<br/>
OR<br/>
480 mg IV over 30 minutes every 4 weeks until disease progression or unacceptable toxicity<br/>
<br/>
Use: As a single agent or in combination with ipilimumab for hepatocellular carcinoma (HCC) who have been previously treated with sorafenib</p><p><b>Usual Adult Dose for Small Cell Lung Cancer:</b></p><p>AS A SINGLE AGENT:<br/>
240 mg IV over 30 minutes every 2 weeks until disease progression or unacceptable toxicity<br/>
<br/>
Use: For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least 1 other line of therapy</p><p><b>Usual Pediatric Dose for Colorectal Cancer:</b></p><p>AS A SINGLE AGENT:<br/>
12 years and older:<br/>
LESS THAN 40 KG:<br/>
3 mg/kg IV over 30 minutes every 2 weeks until disease progression or unacceptable toxicity<br/>
12 years and older:<br/>
40 KG OR GREATER:<br/>
240 mg IV over 30 minutes every 2 weeks until disease progression or unacceptable toxicity<br/>
OR<br/>
480 mg IV over 30 minutes every 4 weeks until disease progression or unacceptable toxicity<br/>
<br/>
IN COMBINATION:<br/>
12 years and older:<br/>
3 mg/kg IV over 30 minutes every 2 weeks with ipilimumab 1 mg/kg IV over 30 minutes on the same day for a total of 4 doses<br/>
AFTER COMPLETING 4 DOSES OF COMBINATION THERAPY, ADMINISTER AS SINGLE AGENT:<br/>
LESS THAN 40 KG:<br/>
3 mg/kg IV over 30 minutes every 2 weeks until disease progression or unacceptable toxicity<br/>
40 KG OR GREATER:<br/>
240 mg IV over 30 minutes every 2 weeks until disease progression or unacceptable toxicity<br/>
OR<br/>
480 mg IV over 30 minutes every 4 weeks until disease progression or unacceptable toxicity<br/>
<br/>
Use: As a single agent or in combination with ipilimumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan in pediatric patients 12 years and older</p><h2>What happens if I miss a dose?</h2><p>Call your doctor for instructions if you miss an appointment for your Opdivo injection.</p><h2>What happens if I overdose?</h2><p>Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.</p><h2 class="ddc-anchor-offset" id="what-to-avoid">What should I avoid while receiving Opdivo?</h2><p>Follow your doctor's instructions about any restrictions on food, beverages, or activity.</p><h2 class="ddc-anchor-offset" id="side-effects">Opdivo side effects</h2><p>Get emergency medical help if you have <b>signs of an allergic reaction to Opdivo:</b> (hives, difficult breathing, swelling in your face or throat) <b>or a severe skin reaction</b> (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).</p><p>Some side effects may occur during the injection. Tell your caregiver right away if you feel dizzy, light-headed, short of breath, itchy, tingly, chilled, or feverish.</p><p>Call your doctor at once if you have:</p><ul>
<li>
<p>severe or ongoing diarrhea, severe stomach pain, bloody or tarry stools;</p>
</li>
<li>
<p>new or worsening skin rash, itching, or blistering;</p>
</li>
<li>
<p>sores or ulcers in your mouth, nose, rectum, or genitals;</p>
</li>
<li>
<p>eye pain, vision changes, sensitivity to light;</p>
</li>
<li>
<p>severe muscle pain or weakness;</p>
</li>
<li>
<p>confusion, memory problems, neck stiffness, drowsiness, balance problems;</p>
</li>
<li>
<p>numbness or tingling in your arms or legs;</p>
</li>
<li>
<p><b>kidney problems</b> - little or no urination, swelling in your feet or ankles, blood in your urine;</p>
</li>
<li>
<p><b>liver problems</b> - severe nausea or vomiting, right-sided upper stomach pain, easy bruising or bleeding, dark urine, jaundice (yellowing of the skin or eyes);</p>
</li>
<li>
<p><b>lung problems</b> - new or worsening cough, chest pain, feeling short of breath;</p>
</li>
<li>
<p><b>signs of a hormonal disorder</b> - frequent or unusual headaches, fast heartbeats, dizziness, fainting, tiredness, mood or behavior changes, hunger, increased thirst or urination, constipation, hair loss, hoarse or deepened voice, sweating, feeling cold, weight gain, or weight loss; or</p>
</li>
<li>
<p>(if you have had a stem cell transplant) feeling sick or uneasy, with pain or swelling near your transplanted organ;</p>
</li>
</ul><p>severe or ongoing diarrhea, severe stomach pain, bloody or tarry stools;</p><p>new or worsening skin rash, itching, or blistering;</p><p>sores or ulcers in your mouth, nose, rectum, or genitals;</p><p>eye pain, vision changes, sensitivity to light;</p><p>severe muscle pain or weakness;</p><p>confusion, memory problems, neck stiffness, drowsiness, balance problems;</p><p>numbness or tingling in your arms or legs;</p><p><b>kidney problems</b> - little or no urination, swelling in your feet or ankles, blood in your urine;</p><p><b>liver problems</b> - severe nausea or vomiting, right-sided upper stomach pain, easy bruising or bleeding, dark urine, jaundice (yellowing of the skin or eyes);</p><p><b>lung problems</b> - new or worsening cough, chest pain, feeling short of breath;</p><p><b>signs of a hormonal disorder</b> - frequent or unusual headaches, fast heartbeats, dizziness, fainting, tiredness, mood or behavior changes, hunger, increased thirst or urination, constipation, hair loss, hoarse or deepened voice, sweating, feeling cold, weight gain, or weight loss; or</p><p>(if you have had a stem cell transplant) feeling sick or uneasy, with pain or swelling near your transplanted organ;</p><p>Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.</p><p>Common Opdivo side effects may include:</p><ul>
<li>
<p>nausea, vomiting, stomach pain, loss of appetite, diarrhea, constipation;</p>
</li>
<li>
<p>feeling weak, tired, or short of breath;</p>
</li>
<li>
<p>hormonal problems;</p>
</li>
<li>
<p>cold symptoms such as runny or stuffy nose, cough, sore throat;</p>
</li>
<li>
<p>fever, body aches;</p>
</li>
<li>
<p>headache, dizziness;</p>
</li>
<li>
<p>itching, rash; or</p>
</li>
<li>
<p>weight loss.</p>
</li>
</ul><p>nausea, vomiting, stomach pain, loss of appetite, diarrhea, constipation;</p><p>feeling weak, tired, or short of breath;</p><p>hormonal problems;</p><p>cold symptoms such as runny or stuffy nose, cough, sore throat;</p><p>fever, body aches;</p><p>headache, dizziness;</p><p>itching, rash; or</p><p>weight loss.</p><p>This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p><h2 class="ddc-anchor-offset" id="interactions">What other drugs will affect Opdivo?</h2><p>Other drugs may interact with nivolumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.</p><h2 class="ddc-anchor-offset" id="faq">Popular FAQ</h2><p>Opdivo (nivolumab) is an immunotherapy used to treat a wide variety of cancer types. How long treatment with this monoclonal antibody prolongs or extends life depends on the type and stage of cancer it is used to treat and other factors. Continue reading</p><p>Results from clinical trial indicate that it can take about 2 months to see a response to treatment with Opdivo, but some patients will respond more quickly and others will take longer.</p><p>Your doctor will order periodic tests, such as CT (computed tomography) and PET (positron emission tomography) scans and MRI (magnetic resonance imaging) to see if you are responding to treatment.  Continue reading</p><p>The key differences between Opdivo (nivolumab) and Keytruda (pembrolizumab) are seen in the dosing frequency, the drugs they are used in combination with and the types of cancer they have been approved for use in. Continue reading</p><p>Opdivo (nivolumab) is an immunotherapy used to treat a variety of cancer types, including melanoma. Durable responses to treatment have been observed following discontinuation of Opdivo therapy. Continue reading</p><p>Pembrolizumab and nivolumab are both prescription medications used to treat various types of cancers, including solid tumors and blood cancers. They may be used alone or in combination with other medicines for cancers that are more advanced, have spread in the body, or are no longer responding to previous treatments. Continue reading</p><h2>More about Opdivo (nivolumab)</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Patient Tips</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>49 Reviews</li>
<li>Drug class: anti-PD-1 monoclonal antibodies</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Head and Neck Cancer</li>
<li>Esophageal Carcinoma</li>
<li>Hepatocellular Carcinoma</li>
<li>Colorectal Cancer</li>
<li data-more-config-id="list-data-resources-conditions">... +8 more</li>
</ul><h2>Further information</h2><p>Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Opdivo only for the indication prescribed.</p><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p><p class="ddc-copyright">Copyright 1996-2021 Cerner Multum, Inc. Version: 15.01.</p></body></html>